YCC Wales is a regional adverse drug reaction monitoring centre, acting on belhalf of the MHRA. Mae CCM Cymru yn un o bum canolfan rhanbarthol monitro sgil-effeithiau i ffeddyginiaethau, sy'n gweithredu ar ran yr Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA). Mae gan CCM Cymru rôl addysgol a chyfathrebu hanfodol i annog adrodd sgil-effeithiau a amheuir drwy'r Cynllun Ce
rdyn Melyn i gleifion a gweithwyr iechyd proffesiynol lleol yng Nghymru. Mae staff CCM Cymru ar gael i roi cyngor ar adrodd Cerdyn Melyn a chynnig sesiynau addysg a hyfforddiant am sgil-effiethiau a amheuir i feddyginiaethau i bob gweithiwr iechyd proffesiynol a grwpiau cleifion. Gall y rhain amrywio o gyfarfodydd anffurfiol bach i ddarlithoedd ffurfiol y gellir eu haddasu i gynnwys:
- Sut i adnabod sgil-effeithiau a amheuir i feddyginiaethau.
- Pwysigrwydd adrodd.
- Beth i'w adrodd ar Gerdyn Melyn.
- Her sgil-effeithiau i feddyginiaethau yng Nghymru.
- Sut mae gwybodaeth Cerdyn Melyn yn cael ei defnyddio.
- Osgoi sgil-effeithiau i feddyginiaethau a rhyngweithiadau.
- Rhagnodi diogel ac effeithiol. Bu staff y Ganolfan yn darlithio, cynnal gweithdai, cyflwyniadau poster a seminarau ar ffarmacolegol i annog adrodd yn ddigymell am sgil-effeithiau i feddyginiaethau gan weithwyr gofal iechyd proffesiynol ac aelodau o'r cyhoedd. Maent wedi parhau i archwilio mecanweithiau eraill i annog adrodd. Mae diwylliant diogelwch cryf yn gofyn am adrodd yn dda am ddigwyddiadau andwyol a digwyddiadau critigol. Mae'n galonogol bod y gyfradd adrodd ar gyfer sgil-effeithiau i feddyginaethau drwy Gynllun Cerdyn Melyn y DU yng Nghymru 50% yn uwch nag ar gyfer y DU gyfan yn 2010 (30.5 vs 19.7 adroddiad fesul 100,000 o'r boblogaeth). Un o'r rhesymau dros y gyfradd adrodd uchel hon yw canlyniad ymdrechion ar y cyd gan weithwyr iechyd proffesiynol, dan arweiniad Canolfan Cerdyn Melyn Cymru ac a gefnogir gan Grŵp Strategaeth Meddyginiaethau Cymru Gyfan (AWMSG), i addysgu cydweithwyr a gweithwyr iechyd proffesiynol yn y dyfodol ynghylch pwysigrwydd adrodd am sgil-effeithiau a amheuir. YCC Wales is one of five regional adverse drug reaction monitoring centres, acting on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA). YCC Wales has a vital educational and communicating role to encourage suspected adverse reaction reporting via the Yellow Card Scheme to both patients and local health professionals in Wales. Staff at YCC Wales are available to give advice on Yellow Card reporting and offer education and training sessions about suspected adverse drug reactions to all health professionals and patient groups. These can range from small informal meetings to formal lectures that can be adapted to cover:
- How to recognise a suspected Adverse Drug Reaction (ADR).
- The importance of reporting.
- What to report on a Yellow Card.
- The challenge of ADRs in Wales.
- How Yellow Card Information is used.
- Avoiding ADRs and interactions.
- Safe and effective prescribing. Staff of the Centre have lectured, held workshops, poster presentations and seminars on pharmacovigilance to encourage the spontaneous reporting of suspected adverse drug reactions from both healthcare professionals and members of the public. They have continued to explore other mechanisms to encourage reporting. A strong safety culture requires good reporting of adverse events and critical incidents. It is encouraging that the reporting rate for suspected adverse drug reactions via the UK Yellow Card scheme in Wales was 50% higher than for the UK as a whole in 2010 (30.5 vs 19.7 reports per 100,000 population). One of the reasons for this high reporting rate is the result of concerted efforts by health professionals, led by the Yellow Card Centre Wales and supported by the All Wales Medicines Strategy Group (AWMSG), to educate colleagues and future health professionals concerning the importance of reporting of suspected ADRs.
